| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_422b57714bf8dd82b486a23bb846a98b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e3bb613a31a6b1402d0907925253dc1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_087bed7abab91ae0f927879f9fe8b273
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84b9be27c339e9c8800ad4a39591f873 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y114-14001 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P7-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-02 |
| filingDate |
2011-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ed159c5d1d6562fabdfe4114b9a154d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e199945569108f94d7cf2a1909029e31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_307dbb19274ddb01ab0266b9382f8988 |
| publicationDate |
2013-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8343744-B2 |
| titleOfInvention |
Regio- and enantioselective alkane hydroxylation with modified cytochrome P450 |
| abstract |
Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-position to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with E. coli , where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8722371-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9322001-B2 |
| priorityDate |
2003-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |